No Early Cardiovascular Risks With Testosterone Treatment
Testosterone treatment for hypogonadism did not increase short- or medium-term risks for cardiovascular events, according to a systematic review and meta-analysis. Cardiovascular risks were similar between men in the testosterone group and those in the placebo group (7.5% vs 7.2%; OR 1.07, 95% CI 0.81-1.42, P=0.62), reported Channa Jayasena, PhD, of Imperial College London, at […]
Another Oral Testosterone Undecanoate OK’d for Hypogonadism
The FDA has approved a new oral testosterone undecanoate capsule (Tlando) for hypogonadism, Antares Pharma announced. This androgen is indicated for testosterone replacement therapy in adult men for conditions associated with a deficiency or absence of endogenous testosterone, including congenital or acquired primary hypogonadism, as well as congenital or acquired hypogonadotropic hypogonadism. “The FDA approval […]
Which Came First: Low Testosterone Levels or Severe COVID-19?
Low testosterone levels in men with symptomatic COVID-19 were associated with a greater risk of severe illness or death, according to Italian researchers. Their case-control study found that, among men admitted to the emergency department of a Milan Hospital during the first wave of the pandemic, the lower the level of testosterone the higher the […]